In AML patients treated with cytarabine, TP53 VAF > 40% was associated with significantly worse overall survival and relapse-free survival compared to lower allelic quantities (4.7 months for VAF > 40% versus 7.3 months for VAF < 40%) [58]. This evidence concerns the gene TP53 and acute myeloid leukemia.